About Kailera
Kailera is a publicly listed company based in Waltham (United States) founded in 2024 by Ron Renaud. Developer of therapies for treating obesity and related conditions. Kailera has raised $1 billion across 2 funding rounds from investors including Royalty Pharma, Citadel and Janus Henderson Investors. The company has 4 employees. Its chief executive, as recorded, is Ron Renaud. Its Indian entity Lera Consulting Structural Engineers (India) Private Limited reported revenue of ₹22.92 Cr. Kailera offers products and services including KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729. Its focus areas include Life Sciences, Obesity, Drugs and GLP-1 Based. Its competitors include Sana Biotechnology, Semma Therapeutics and Rezolute; 2 of its 3 listed competitors have raised funding.
Company details
Kailera was founded in 2024 and is based in Waltham, United States. Focus is placed on the biotechnology sector, where therapies for obesity and type 2 diabetes are developed. A pipeline of candidates is maintained, including KAI-9531 as an injectable GLP-1GIP receptor dual agonist and KAI-7535 as an oral small molecule. Operations center on advancing these treatments for metabolic conditions.
- Headquarters Waltham, United States
- Employees 4
- Founders Ron Renaud
- Stage Public
- SectorsHealthcare
- Website kailera.com
- Social LinkedIn X
- Legal Name Kailera Therapeutics Inc
- Indian entity revenue₹22.92 Cr
FY 2025 · +97% YoY
- Indian entity net profit₹8.50 Cr
FY 2025 · 37% margin
- Indian entity EBITDA₹11.72 Cr
FY 2025 · 51% margin
- Total Equity Funding$1B (USD)
in 2 rounds
- Latest Funding Round$600M (USD), Series B
Oct 2025
- InvestorsRoyalty Pharma
& 13 more
- Employee Count4
Associated legal entities of Kailera
Kailera operates through Lera Consulting Structural Engineers (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Lera Consulting Structural Engineers (India) Private Limited CIN U74210MH2009PTC268790 | Active | 02 Jan 2009 | Mumbai, Maharashtra | ₹22.9 Cr | 4 | 4 | View details |
Products & Services of Kailera
Kailera offers a comprehensive portfolio of products and services, including KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729.
Dual agonist for treating obesity and type 2 diabetes effectively.
Small molecule agonist targeting obesity and diabetes management.
Daily tablet for obesity and diabetes treatment development.
Tri-agonist peptide for obesity and related conditions.
Funding Insights of Kailera
Kailera has successfully raised a total of $1B across 2 strategic funding rounds. The most recent funding activity was a Series B round of $600 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1B
- Total Rounds 2
- Last Round Series B — $600M
- First Round $400M
(Oct 2024)
- Investors Count 14
All 2 funding rounds of Kailera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $600M | Series B | – | Bain Capital Private Equity | |
| Oct 2024 | $400M | Series A | – | Atlas Venture, Bain Capital Life Sciences |
14 investors in total: 14 institutional.
Investors in Kailera
Kailera has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Royalty Pharma, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Private investment firm managing assets and expanding into equity, credit, and real estate services. | 1984 | baincapitalprivateequity.com | London, United Kingdom | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Healthcare innovation is supported through venture capital investments. | sironacap.com | |||
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Pension fund assets are managed for sustainable long-term growth. | 1997 | cppinvestments.com | Toronto, Canada |
Investor details for Kailera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Lera Consulting Structural Engineers (India) Private Limited (Kailera)
Lera Consulting Structural Engineers (India) Private Limited is the primary company behind Kailera. The board of Lera Consulting Structural Engineers (India) Private Limited currently have 4 directors; the longest-serving is William James Faschan, appointed in 2009. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| William James Faschan DIN 02164530 | Director | 02 Jan 2009 | 17 yrs 10 mo | Lera Consulting Structural Engineers (India) Private Limited |
| Nayankumar Bhanushanker Trivedi DIN 02311096 | Director | 02 Jan 2009 | 17 yrs 10 mo | Lera Consulting Structural Engineers (India) Private Limited |
| Daniel Aloysius Sesil DIN 02164620 | Director | 12 Dec 2011 | 14 yrs 10 mo | Lera Consulting Structural Engineers (India) Private Limited |
| Manish Premji Maru DIN 07177926 | Director | 07 May 2015 | 11 yrs 6 mo | Lera Consulting Structural Engineers (India) Private Limited |
People of Kailera
1 people are tracked at Kailera (1 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Ron Renaud | Founder & CEO | Leadership |
Complete people profiles for Kailera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kailera
Kailera is a publicly listed company on the NASDAQ with ticker symbol KLRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Apr 2026
- Listed onNASDAQ: KLRA
- Listed entityKAILERA THERAPEUTICS INC
- Exchange sectorHealth technology
- ISINUS4829311020
- Share price$10.77 (-4.94% on the day) · 2026-10-13
- Market capitalisation$1.40B
- Volume (last session)1,106,634
Financials of Kailera
Figures of Lera Consulting Structural Engineers (India) Private Limited, the primary company behind Kailera, for FY 2025. Revenue was ₹22.92 Cr (+97% year on year). Net profit was ₹8.50 Cr (37% margin). EBITDA was ₹11.72 Cr (51% margin). Revenue has grown at a compounded annual rate of +58% over three years and +34% over five years.
- ₹22.92 CrRevenue · FY 2025 · +97% YoY
- ₹8.50 CrNet profit · 37% margin
- ₹11.72 CrEBITDA · 51% margin
- ₹1.7 LakhPaid-up capital
- 4Employees (provident fund records)
- +58%Revenue CAGR, 3 years
- +34%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Lera Consulting Structural Engineers (India) Private Limited are on its company page.
Detailed financial statements for Kailera
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kailera
4 dated milestones of Kailera across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Kailera is founded.
- Funding First funding round of $400.0M.
- Funding Latest funding round, Series B, of $600.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Kailera
Kailera has 3 listed competitors in our database, 2 of them funded. They include Sana Biotechnology, Semma Therapeutics and Rezolute.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. |
Detailed competitors of Kailera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kailera
The website of Kailera (kailera.com) receives about 8.5K visits a month.
- Monthly visits8.5K
▲ 104.9% vs previous month
Top companies in Diabetes
3 companies that operate in the same segment as Kailera (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kailera
Complete news archive for Kailera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kailera
Kailera was founded in 2024.
Kailera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Ron Renaud is the CEO of Kailera, as recorded in our data. They have also founded this company.
Kailera is a funded company, having raised a total of $1B across 2 funding rounds to date. The company's 1st funding round was a Series A of $400M, raised on Oct 2024.
Kailera has 4 employees.
The primary company behind Kailera, Lera Consulting Structural Engineers (India) Private Limited, reported revenue of ₹22.92 Cr for FY 2025, up 97% year on year.
Kailera was founded in 2024 and is based in Waltham, United States. Focus is placed on the biotechnology sector, where therapies for obesity and type 2 diabetes are developed. A pipeline of candidates is maintained, including KAI-9531 as an injectable GLP-1GIP receptor dual agonist and KAI-7535 as an oral small molecule. Operations center on advancing these treatments for metabolic conditions.
Kailera's top competitors include Sana Biotechnology, Semma Therapeutics and Rezolute.
Kailera offers KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729.
Yes, Kailera is publicly traded on NASDAQ under the ticker symbol KLRA.
Kailera has 14 investors. Key investors include Royalty Pharma, Citadel, Janus Henderson Investors, CPP Investments, and RTW Investments.
Kailera operates through Lera Consulting Structural Engineers (India) Private Limited.